MaxCyte, Inc. Notice of Results (9483I)
August 14 2019 - 2:02AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9483I
MaxCyte, Inc.
14 August 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Half Year Results
Gaithersburg, Maryland - 14 August 2019: MaxCyte (LSE: MXCT,
MXCS), the global clinical-stage cell-based therapies and life
sciences company, will announce its interim results for the six
months ended 30 June 2019 on Wednesday 18 September 2019.
Doug Doerfler, Chief Executive Officer, and Ron Holtz, Chief
Financial Officer, will host a presentation and live conference
call for analysts at 11.00am BST on the day of the results at 1
Cornhill, London, EC3V 3NR.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation(R) Technology to enable
its biopharmaceutical partners to advance the development of
innovative medicines, particularly in cell therapy. MaxCyte has
placed its flow electroporation instruments worldwide, including
with all of the top ten global biopharmaceutical companies. The
Company now has more than 80 partnered programme licenses in cell
therapy with more than 45 licensed for clinical use, including four
announced commercial licenses with aggregate potential milestones
of more than $250m. With its robust delivery technology platform,
MaxCyte helps its partners to unlock the full potential of their
products. For more information, visit www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORPJMBTMBBBTIL
(END) Dow Jones Newswires
August 14, 2019 02:02 ET (06:02 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024